{"id":"NCT00574548","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS","officialTitle":"A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2010-02","completion":"2010-02","firstPosted":"2007-12-17","resultsPosted":"2011-05-09","lastUpdate":"2011-07-22"},"enrollment":720,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"13 valent Pneumococcal Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"13 valent Pneumococcal Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"13 valent Pneumococcal Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"23-valent Pneumococcal Polysaccharide Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"23-valent Pneumococcal Polysaccharide Vaccine","otherNames":[]}],"arms":[{"label":"Group 1.1","type":"EXPERIMENTAL"},{"label":"Group 1.2","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to compare the safety, tolerability and immunologic response to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that have never received a previous dose of 23vPS.","primaryOutcome":{"measure":"Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 23vPS (Year 0)","timeFrame":"1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1)","effectByArm":[{"arm":"13vPnC / 23vPS","deltaMin":148,"sd":null},{"arm":"23vPS","deltaMin":148,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":["24606865"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6115A1-3010&StudyName=Study%20Evaluating%20the%20Safety%2C%20Tolerability%20and%20Immunogenicity%20of%2013vPnC%20as%20a%202-Dose%20Regimen%20or%20with%2023vPS"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":478},"commonTop":["Pain (Any)","Pain (Any)","Pain (Mild)","Pain (Any)","Pain (Mild)"]}}